H.R.2471 - Right Drug Dose Now Act of 2025 (119th Congress)
Summary
H.R.2471, the Right Drug Dose Now Act of 2025, aims to update the National Action Plan for Adverse Drug Event Prevention by incorporating advances in pharmacogenomic research and testing. The bill seeks to improve electronic health records (EHRs) to include pharmacogenomic information, thereby reducing adverse drug events. It mandates reports, guidance, and updates to existing systems to better utilize genetic information in prescribing practices.
Expected Effects
This act will likely lead to more personalized medicine by integrating genetic testing into drug prescription protocols. Healthcare providers will receive updated guidance and tools to make better-informed decisions, potentially reducing adverse drug reactions. The FDA's adverse event reporting system will also be updated to include optional reporting of drug-gene interactions.
Potential Benefits
- Reduced adverse drug events through personalized medicine.
- Improved healthcare provider knowledge and decision-making via updated guidelines.
- Enhanced electronic health record systems for better integration of pharmacogenomic data.
- More comprehensive adverse event reporting to the FDA.
- Increased patient awareness and consideration of pharmacogenomic testing.
Potential Disadvantages
- Potential costs associated with increased genetic testing.
- Privacy concerns related to genetic data in health records.
- Increased complexity for healthcare providers in interpreting and applying pharmacogenomic information.
- Possible disparities in access to testing based on socioeconomic factors.
- The need for continuous updates and maintenance of EHR systems and guidelines.
Constitutional Alignment
The bill aligns with the Constitution's general welfare clause (Preamble) by promoting public health and safety through improved healthcare practices. It does not appear to infringe upon any specific constitutional rights or limitations. The establishment of guidelines and reporting requirements falls within the purview of Congress's power to regulate interstate commerce (Article I, Section 8) as it relates to pharmaceuticals and healthcare.
Impact Assessment: Things You Care About ⓘ
This action has been evaluated across 19 key areas that matter to you. Scores range from 1 (highly disadvantageous) to 5 (highly beneficial).